Natera (NASDAQ:NTRA) Given New $200.00 Price Target at Piper Sandler

Natera (NASDAQ:NTRA) had its price objective boosted by Piper Sandler from $150.00 to $200.00 in a research note published on Monday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

Several other analysts have also recently commented on NTRA. JPMorgan Chase & Co. boosted their price target on Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 13th. Leerink Partners boosted their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Craig Hallum boosted their price target on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Stephens reiterated an “overweight” rating and set a $125.00 price target on shares of Natera in a research report on Friday, August 9th. Finally, StockNews.com cut Natera from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $140.59.

Natera Price Performance

Natera stock opened at $153.42 on Monday. Natera has a 12 month low of $53.31 and a 12 month high of $167.79. The business has a 50 day simple moving average of $127.38 and a 200-day simple moving average of $115.76. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business’s revenue was up 63.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.95) earnings per share. Analysts anticipate that Natera will post -1.7 EPS for the current year.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 5,024 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the transaction, the chief executive officer now owns 195,686 shares of the company’s stock, valued at approximately $25,141,737.28. This represents a 2.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Rowan E. Chapman sold 2,614 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $127.68, for a total value of $333,755.52. Following the transaction, the director now directly owns 7,969 shares in the company, valued at approximately $1,017,481.92. The trade was a 24.70 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,821 shares of company stock valued at $4,776,878 in the last quarter. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Natera

Hedge funds have recently bought and sold shares of the company. Itau Unibanco Holding S.A. acquired a new position in Natera during the 2nd quarter worth about $28,000. Quarry LP lifted its stake in Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares in the last quarter. GAMMA Investing LLC increased its holdings in Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the period. Covestor Ltd increased its holdings in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the period. Finally, True Wealth Design LLC purchased a new stake in Natera during the 3rd quarter worth about $57,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.